Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships

Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) said its Indian joint venture CoSara Diagnostics expanded distributor engagement by exhibiting at two regional conferences (GAPM in Gujarat on Jan 10-11 and ACLAP in Maharashtra) and has an existing network of over 40 distributors across India.

CoSara is preparing to assist in clinical performance studies for the Co-Dx PCR Mycobacterium Tuberculosis (MTB) Test on the Co-Dx PCR platform and will participate in manufacturing the PCR Pro instrument and MTB test cups to align with India’s "Make in India" initiative. The Co-Dx PCR platform remains subject to review by the FDA and other regulators and is not yet available for sale.

Positive

• Existing distributor network of >40 channels across India
• Participation in two regional conferences to generate customer leads
• Preparing to assist clinical performance studies for Co-Dx MTB test
• Planned local manufacturing of PCR Pro and MTB test cups in India

Negative

• Co-Dx PCR platform is under regulatory review and not available for sale
• Clinical performance studies pending before commercial deployment

News Market Reaction

-3.39% 15.5x vol

21 alerts

-3.39% News Effect

-56.2% Trough in 1 hr 1 min

-$396K Valuation Impact

$11M Market Cap

15.5x Rel. Volume

On the day this news was published, CODX declined 3.39%, reflecting a moderate negative market reaction. Argus tracked a trough of -56.2% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $396K from the company's valuation, bringing the market cap to $11M at that time. Trading volume was exceptionally heavy at 15.5x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Distributor base: over 40 distributors GAPM conference edition: 44th GAPM conference dates: January 10–11 +1 more

4 metrics

Distributor base over 40 distributors Existing CoSara distributor network across India

GAPM conference edition 44th Gujarat Association of Pathologists & Microbiologists conference

GAPM conference dates January 10–11 Conference timing in Gujarat, India

ACLAP conference edition 13th Association of Clinical Laboratory Analysts & Practitioners in Maharashtra

Market Reality Check

Price: $3.00 Vol: Volume 35,317 is below th...

low vol

$3.00 Last Close

Volume Volume 35,317 is below the 20-day average of 80,507, suggesting limited pre-news activity. low

Technical Shares at $6.19 are trading below the 200-day MA of $9.75 and 86.69% under the 52-week high.

Peers on Argus

CODX was modestly higher while peers showed mixed moves: INBS up 15.61%, AIMD up...

2 Up

CODX was modestly higher while peers showed mixed moves: INBS up 15.61%, AIMD up 2.20%, but XAIR down 7.71% and NXL down 3.73%, pointing to stock-specific rather than broad sector momentum.

Historical Context

5 past events · Latest: Dec 30 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 30	Reverse stock split	Negative	-21.2%	1-for-30 reverse split to address Nasdaq minimum bid requirement.
Dec 29	IP / patent grant	Positive	-2.5%	Australian patent granted for Co-Dx PCR platform technologies and Co-Primers®.
Dec 18	JV participation event	Positive	+5.3%	CoSara joined advanced TB diagnostics course in Chennai, India.
Dec 17	Clinical validation work	Positive	+6.5%	In silico analysis confirmed maintained Logix Smart ABC test reactivity.
Dec 09	Conference presentation	Positive	+4.5%	Presentation on Co-Dx PCR platform and AI integration at POC Testing 2025.

Pattern Detected

Recent positive technology and partnership updates generally saw positive price alignment, while the reverse stock split announcement drew a sharply negative reaction.

Recent Company History

Over the past month, CODX combined strategic platform progress with balance sheet stress. A 1-for-30 reverse split effective Jan 2, 2026 was followed by this distributor-focused India JV update. Earlier, CODX secured an Australian patent for the Co-Dx PCR platform and highlighted AI integration at a Dec 9, 2025 conference. CoSara’s TB-related participation in India and influenza Co‑Primers® analysis underscored diagnostic depth. Today’s news continues that theme of expanding Co-Dx PCR platform visibility and channel reach.

Market Pulse Summary

This announcement highlights CoSara’s efforts to deepen market access in India, leveraging regional ...

Analysis

This announcement highlights CoSara’s efforts to deepen market access in India, leveraging regional conferences to expand an existing network of over 40 distributors and introduce SARAGENE® assays and the Co-Dx PCR platform. It also notes upcoming clinical performance studies for the MTB test and local manufacturing aligned with “Make in India.” In context of recent platform, TB, and IP updates, investors may watch future data from these studies and tangible revenue contributions from the India JV to assess impact.

Key Terms

molecular diagnostics, pcr, mycobacterium tuberculosis, clinical performance studies

4 terms

molecular diagnostics medical

"a molecular diagnostics company with a unique, patented platform"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

pcr medical

"upcoming Co-Dx™ PCR platform*, to new customers"

PCR (polymerase chain reaction) is a laboratory method that makes many copies of a tiny piece of genetic material (DNA or RNA) so scientists can detect and study it reliably — think of photocopying a faint, tiny note until the words are easy to read. For investors, PCR matters because it underpins diagnostic tests, drug development, and biotech tools whose sales, regulatory approvals, and real-world use can materially affect company revenues and market perceptions during health events or product launches.

mycobacterium tuberculosis medical

"Co-Dx PCR Mycobacterium Tuberculosis (MTB) Test on the Co-Dx PCR platform"

Mycobacterium tuberculosis is the bacterium that causes tuberculosis (TB), a contagious lung infection that can become chronic and hard to treat. Think of it as a stubborn weed that can survive in the body and, in some cases, resist standard treatments; this matters to investors because the threat of drug-resistant strains, new diagnostics, vaccines, or treatments can drive demand, regulatory scrutiny, public health spending, and the commercial prospects of healthcare companies.

clinical performance studies medical

"prepares to assist in the clinical performance studies for the Co-Dx PCR"

Clinical performance studies are organized tests that measure how a medical product, device, test, or treatment works in real patients and real care settings, focusing on safety, accuracy and whether it delivers the expected health benefits. Investors watch these studies because their results influence regulatory approval, market access and sales potential — like a road test that shows whether a new car is safe and reliable before dealers and buyers commit.

AI-generated analysis. Not financial advice.

SALT LAKE CITY, Jan. 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has been strengthening its distributor base across India, recently attending and participating in two regional conferences.

The events provided opportunities for CoSara to introduce its SARAGENE® diagnostic products, as well as the upcoming Co-Dx™ PCR platform*, to new customers and to expand its existing base of over 40 distributors across the country.

The conferences come as CoSara prepares to assist in the clinical performance studies for the Co-Dx PCR Mycobacterium Tuberculosis (MTB) Test on the Co-Dx PCR platform. CoSara will also participate in manufacturing the PCR Pro™ instrument and MTB test cups to align with the "Make in India" initiative.

CoSara exhibited at the 44^th Gujarat Association of Pathologists & Microbiologists ("GAPM") conference in Gujarat which took place on January 10-11. The 13^th Association of Clinical Laboratory Analysts & Practitioners ("ACLAP") in Maharashtra took place during the same time.

*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-jv-cosara-participates-in-regional-conferences-to-grow-and-strengthen-distributor-relationships-302658374.html

SOURCE Co-Diagnostics

FAQ

What did Co-Diagnostics (CODX) announce about CoSara on January 12, 2026?

CoSara expanded distributor engagement by exhibiting at GAPM and ACLAP and has over 40 distributors in India.

Will CoSara manufacture the Co-Dx PCR Pro instrument in India (CODX)?

Yes, CoSara said it will participate in manufacturing the PCR Pro instrument and MTB test cups to support "Make in India."

Is the Co-Dx PCR platform available for sale now (CODX)?

No, the Co-Dx PCR platform is subject to FDA and other regulatory review and is not yet available for sale.

What is CoSara’s role in the Co-Dx MTB test rollout (CODX)?

CoSara will assist in clinical performance studies for the Co-Dx PCR MTB test and help manufacture related instruments and test cups.

Which conferences did CoSara attend to grow distributor relationships in India?

CoSara exhibited at the 44th GAPM in Gujarat (Jan 10-11) and the 13th ACLAP in Maharashtra during the same period.